Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENVBNASDAQ:KZIANASDAQ:LSDINASDAQ:SXTP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENVBEnveric Biosciences$1.26-3.8%$1.38$1.01▼$14.18$3.12M0.68730,566 shs97,504 shsKZIAKazia Therapeutics$3.40-6.6%$3.92$2.86▼$79.00$3.42M2.49174,180 shs25,041 shsLSDILucy Scientific Discovery$0.03$0.44▼$12.80$907K1.41640,390 shs314,500 shsSXTP60 Degrees Pharmaceuticals$2.15-4.4%$2.37$1.41▼$35.99$3.17M3.02551,081 shs59,073 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENVBEnveric Biosciences-8.13%+6.94%+3.15%-17.61%-89.36%KZIAKazia Therapeutics+1.11%+11.83%-7.77%-22.53%-74.88%LSDILucy Scientific Discovery0.00%0.00%0.00%0.00%-23.30%SXTP60 Degrees Pharmaceuticals-5.86%-2.17%-30.98%-28.13%+105.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENVBEnveric Biosciences2.1524 of 5 stars3.53.00.00.01.50.01.3KZIAKazia Therapeutics3.1297 of 5 stars3.53.00.00.03.30.00.0LSDILucy Scientific DiscoveryN/AN/AN/AN/AN/AN/AN/AN/ASXTP60 Degrees Pharmaceuticals0.2202 of 5 stars0.02.00.00.01.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENVBEnveric Biosciences 3.00Buy$10.00693.65% UpsideKZIAKazia Therapeutics 3.00Buy$57.501,591.18% UpsideLSDILucy Scientific Discovery 0.00N/AN/AN/ASXTP60 Degrees Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest LSDI, KZIA, ENVB, and SXTP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/10/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)4/24/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)4/8/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/28/2025SXTP60 Degrees PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/22/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/7/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/6/2025ENVBEnveric BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.002/25/2025SXTP60 Degrees PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral2/19/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENVBEnveric BiosciencesN/AN/AN/AN/A$10.71 per shareN/AKZIAKazia Therapeutics$2.31M1.48N/AN/A($1.97) per share-1.73LSDILucy Scientific Discovery$16.73K0.00N/AN/A$2.86 per share0.00SXTP60 Degrees Pharmaceuticals$607.57K5.21N/AN/A($10.45) per share-0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENVBEnveric Biosciences-$17.29M-$38.38N/AN/AN/AN/A-221.54%-164.32%N/AKZIAKazia Therapeutics-$17.56MN/A0.00∞N/AN/AN/AN/AN/ALSDILucy Scientific Discovery-$8.99M-$7.00N/AN/AN/AN/A-294.74%-137.65%N/ASXTP60 Degrees Pharmaceuticals-$3.77M-$50.41N/AN/AN/AN/AN/A-113.43%5/21/2025 (Estimated)Latest LSDI, KZIA, ENVB, and SXTP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025SXTP60 Degrees Pharmaceuticals-$1.31-$1.56-$0.25-$1.56N/AN/A5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENVBEnveric BiosciencesN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/ALSDILucy Scientific DiscoveryN/AN/AN/AN/AN/ASXTP60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENVBEnveric BiosciencesN/A5.175.17KZIAKazia TherapeuticsN/A0.240.24LSDILucy Scientific DiscoveryN/A0.380.38SXTP60 Degrees PharmaceuticalsN/A5.264.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENVBEnveric Biosciences13.82%KZIAKazia Therapeutics30.89%LSDILucy Scientific Discovery72.61%SXTP60 Degrees Pharmaceuticals7.96%Insider OwnershipCompanyInsider OwnershipENVBEnveric Biosciences1.10%KZIAKazia Therapeutics1.00%LSDILucy Scientific DiscoveryN/ASXTP60 Degrees Pharmaceuticals10.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENVBEnveric Biosciences202.47 million656,000Not OptionableKZIAKazia Therapeutics121.01 million4.99 millionOptionableLSDILucy Scientific Discovery21.77 millionN/ANot OptionableSXTP60 Degrees Pharmaceuticals31.47 million6.61 millionNot OptionableLSDI, KZIA, ENVB, and SXTP HeadlinesRecent News About These Companies60 Degrees Pharmaceuticals Announces First Quarter 2025 ResultsMay 15 at 4:31 PM | globenewswire.com60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns Sell (E+) Rating from Weiss RatingsMay 12 at 1:15 AM | americanbankingnews.comBabesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma SurveyApril 22, 2025 | globenewswire.comWhy 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?April 10, 2025 | insidermonkey.comGeoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21April 10, 2025 | globenewswire.comGeoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21April 10, 2025 | globenewswire.comSixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public HealthApril 8, 2025 | globenewswire.com60 Degrees Pharmaceuticals, Inc.April 4, 2025 | uk.investing.com60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVFebruary 21, 2025 | accessnewswire.com60 Degrees Pharmaceuticals announces 1-for-5 reverse stock splitFebruary 20, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals, Inc. Announces 1-for-5 Reverse Stock Split to Comply with Nasdaq Listing RequirementsFebruary 20, 2025 | quiverquant.com60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock SplitFebruary 20, 2025 | globenewswire.com60 Degrees says FDA does not object to tafenoquine import planFebruary 11, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals, Inc. Receives FDA Approval for Importing KODATEF® as Preemptive Measure for ARAKODA® Supply StabilityFebruary 11, 2025 | quiverquant.comSixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®February 11, 2025 | globenewswire.comInsiders Give Up US$71k As 60 Degrees Pharmaceuticals Stock Drops To US$0.55February 9, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals, Inc. Closes Registered Direct Offering and Concurrent Private Placement Raising Approximately $1.075 MillionFebruary 6, 2025 | quiverquant.com60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesFebruary 6, 2025 | globenewswire.com60 Degrees prices 1.5M shares at 71.5c in registered direct offeringFebruary 5, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals, Inc. Announces $1.075 Million Registered Direct Offering and Concurrent Private Placement of Common Stock and WarrantsFebruary 5, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLSDI, KZIA, ENVB, and SXTP Company DescriptionsEnveric Biosciences NASDAQ:ENVB$1.26 -0.05 (-3.82%) As of 03:59 PM EasternEnveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Kazia Therapeutics NASDAQ:KZIA$3.40 -0.24 (-6.59%) As of 03:59 PM EasternKazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Lucy Scientific Discovery NASDAQ:LSDILucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.60 Degrees Pharmaceuticals NASDAQ:SXTP$2.15 -0.10 (-4.44%) As of 04:00 PM Eastern60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
